US FDA to hold public nanotechnology meeting
The US Food and Drug Administration (FDA) has announced plans to hold a public meeting in Autumn 2006 to gather information about and further its understanding of current developments in uses of nanotechnology materials in FDA regulated products.
The US Food and Drug Administration (FDA) has announced plans to hold a public meeting in Autumn 2006 to gather information about and further its understanding of current developments in uses of nanotechnology materials in FDA regulated products.
"Due to the small size and special properties of nanotechnology materials, they have great potential for use in a vast array of FDA-regulated products," reads an FDA statement. "These small materials often have physical or chemical properties that are different than those of their larger counterparts [and] have the potential to lead to scientific advances. For example, this technology could be used to create new drug formulations and routes of delivery to previously inaccessible sites in the body."
The FDA is particularly interested in hearing about: new types of nanotechnology products under development in the areas dietary supplements, cosmetics, human and animal drugs, human biologics and medical devices; specific scientific issues related to the development of these products relevant to FDA's regulation of them; if there are opportunities for the agency to address hurdles that may be inhibiting the use of nanotechnology in medical product development, and issues about which regulated industry, academia, and the interested public may wish to inform FDA concerning the use of nanotechnology in FDA-regulated products.
While the agency is not accepting registrations the moment, it is interested in receiving expressions of interest from those intending to attend or present at the meeting. Anyone interested should contact Poppy Kendall at Poppy.Kendall@FDA.HHS.GOV or on +1 301 827 3360. Comments may also be submitted electronically at www.accessdata.fda.gov/scripts/oc/dockets/comments/getDocketInfo.cfm?EC_DOCUMENT_ID=1013&SORT=&MAXROWS=15&START=16&CID=&AGENCY=FDA or mailed to the Division of Dockets Management (HFA), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852. All comments should be identified with Docket Number 2006N-0107.
Updates on the event can be found at www.fda.gov/nanotechnology.